October 1, 2021 09:45 AM EDTUpdated 10:05 AM
FDA+

Omeros stock craters as FDA cites de­fi­cien­cies in ap­pli­ca­tion for HSCT-TMA drug

Zachary Brennan

Senior Editor

Omeros’ stock price fell by more than 40% in ear­ly trad­ing Fri­day as the com­pa­ny dis­closed that the FDA has found de­fi­cien­cies in its ap­pli­ca­tion …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
ENDPOINTS CAREERS

‭ Regulatory Lead / Head of Regulatory‬

Autonomy Bio Inc.

San Francisco, CA 94107, USA

TRENDING NOW

As­traZeneca de­tails its oral SERD 'switch­ing' reg­i­men as fea­si­bil­i­ty ques­tions re­main

Sum­mit says bis­pe­cif­ic miss­es over­all sur­vival in close­ly-watched lung can­cer study

Sum­mit’s dis­ap­point­ing sur­vival read­out rais­es stakes for full da­ta

As life-sav­ing check­point drugs move to ear­li­er can­cers, re­searchers de­bate how best to use them

Arv­inas, Pfiz­er's PRO­TAC in breast can­cer no bet­ter than oral SERDs

sponsored

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

A service from the Financial Times